A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage ? lung adenocarcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-16008316

Enrollment

Unknown

Registered

2016-04-19

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stage ? lung adenocarcinoma

Interventions

Trial Group:thoracic intensity-modulated radiotherapy

Trial Group:chemotherapy

Eligibility

Sex/Gender

All

Age

48 Years to 68 Years

Inclusion criteria

Inclusion criteria: Patients with histologically or cytologically con?rmed adenocarcinoma stage IIIA/IIIB, deemed unresectable by the Lung Cancer International Staging System, were eligible. Each patient was a candidate for de?nitive radiotherapy. Other eligibility criteria included the following: measurable or assessable disease as dened by the response evaluation criteria in solid tumours (RECIST) criteria, performance status (PS) of 0 or 1, absolute neutrophil >=2000 cells/uL, and platelet count >=100,000/uL; hemoglobin level >=9g/dL; calculated creatinine clearance >=60 mL/min; bilirubin level 1.0L.

Exclusion criteria

Exclusion criteria: Exclusion criteria comprised previous surgery, radiation or chemotherapy; >5% weight loss; clinically significant medical or psychiatric disorders.

Design outcomes

Primary

Measure	Time frame
MTD;PFS;OS;	—

Secondary

Measure	Time frame
response rate;	—

Countries

China

Contacts

Public ContactLu Yiyu

Nanhai Hospital of Southern Medical University

lu_yiyu@163.com+86 13925996488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026